MAPT and cognitive disorder: For plasma p-tau181, our results are consistent with the Coomans, et al. who showed that plasma pTau181 had high accuracy in identifying Aβ pathology in the preclinical stage of dementia (AUC 0.83; 95% CI 0.7–0.96); however, to differentiate cognitive disease staging, plasma pTau181 (AUC 0.74) had lower performance than Tau PET imaging at temporal region (AUC 0.92) (31).